ArticleJournal of asthma and allergy2025
Serum Periostin as a Potential Biomarker in the Evaluation of Allergic Rhinitis: A Pilot Study.
Article in Journal of asthma and allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Periostin in allergic rhinitis: from pathogenic mediator to predictive biomarker and therapeutic target.Frontiers in pharmacology · 2026Pooled it
- The Past, the Present, and the Future of Periostin in Allergy.Allergy, asthma & immunology research · 2026Review
- Role of Periostin in the Development of Nasal Hyperresponsiveness in Mice with Allergic Rhinitis.International journal of molecular sciences · 2026Article
- Analysis of Periostin, TGF-β, and SLUG Expression in Inflammatory Bowel Disease in Pediatric Patients and Their Clinical Implications.Journal of clinical medicine · 2026Article
- Advances in clinical examination techniques for allergic rhinitis: a review from traditional testing to precision diagnosis.Frontiers in allergy · 2026Review
- Review
- Plasma MRGPRX2 Correlates with Severity of Artemisia-Induced Allergic Rhinitis, Particularly in IgE-Negative Patients: A Cross-Sectional Study.Journal of asthma and allergy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Although periostin has recently emerged as a new mediator in chronic allergic diseases, particularly in upper airway disease, its significance as a biomarker for allergic rhinitis (AR) is still unclear. Therefore, we aimed to assess the potential of periostin as a novel candidate biomarker for diagnosing and assessing the severity of AR. Patients and Methods: A total of 40 patients with AR and 22 healthy controls, all aged over 18 years, were recruited for the study. Participants underwent examinations to assess serum levels of total IgE (tIgE), specific IgE (sIgE), periostin, and remodeling-related factors, as well as fractional exhaled nitric oxide (FeNO) and fractional nasal nitric oxide (FnNO). Additionally, clinical characteristics questionnaire and nasal function assessments were completed by AR patients. Results: The levels of serum periostin were significantly higher in patients with AR compared to healthy controls (Z=-3.605, Conclusion: Serum periostin shows potential as a candidate biomarker for detecting AR and can serve as a surrogate biomarker for assessing airway inflammation in AR patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.